Intech Investment Management LLC Acquires 22,858 Shares of Biohaven Ltd. (NYSE:BHVN)

Intech Investment Management LLC grew its holdings in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 202.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 34,165 shares of the company's stock after acquiring an additional 22,858 shares during the period. Intech Investment Management LLC's holdings in Biohaven were worth $1,276,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Point72 Asset Management L.P. lifted its position in shares of Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock worth $74,969,000 after purchasing an additional 1,322,922 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Biohaven by 563.4% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company's stock worth $25,416,000 after buying an additional 431,954 shares during the last quarter. JPMorgan Chase & Co. grew its position in shares of Biohaven by 85.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company's stock worth $40,448,000 after acquiring an additional 372,737 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Biohaven by 5.6% during the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock valued at $311,142,000 after acquiring an additional 328,099 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in shares of Biohaven by 600.9% during the 3rd quarter. Wellington Management Group LLP now owns 243,167 shares of the company's stock valued at $12,151,000 after acquiring an additional 208,472 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Buying and Selling

In other news, Director John W. Childs acquired 32,700 shares of Biohaven stock in a transaction that occurred on Tuesday, March 4th. The stock was purchased at an average price of $30.47 per share, with a total value of $996,369.00. Following the completion of the transaction, the director now owns 2,320,571 shares in the company, valued at approximately $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 16.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have weighed in on BHVN shares. Morgan Stanley lowered their target price on shares of Biohaven from $69.00 to $63.00 and set an "overweight" rating for the company in a research note on Friday, March 7th. JPMorgan Chase & Co. dropped their price objective on shares of Biohaven from $72.00 to $68.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 5th. Cantor Fitzgerald restated an "overweight" rating on shares of Biohaven in a research note on Tuesday, December 17th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 target price on shares of Biohaven in a report on Tuesday, March 4th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 price target on shares of Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Fourteen investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $62.77.

Biohaven Trading Down 3.4 %

Shares of BHVN traded down $1.03 during midday trading on Wednesday, hitting $28.85. The stock had a trading volume of 821,205 shares, compared to its average volume of 975,910. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $57.07. The business has a 50-day simple moving average of $35.65 and a two-hundred day simple moving average of $41.56. The firm has a market cap of $2.94 billion, a P/E ratio of -3.09 and a beta of 1.27.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.29). On average, analysts expect that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.